Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
139.4 USD | +0.24% | +0.60% | +5.83% |
Business Summary
Number of employees: 1,400
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100.0
%
| 1,489 | 100.0 % | 1,887 | 100.0 % | +26.76% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1,489 | 100.0 % | 1,887 | 100.0 % | +26.76% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Eiry Roberts
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-01-07 |
Bill Wilson
COO | Chief Operating Officer | - | 96-08-31 |
Chief Tech/Sci/R&D Officer | 65 | 92-12-31 | |
Gary Lyons
BRD | Director/Board Member | 73 | 93-01-31 |
Todd Tushla
IRC | Investor Relations Contact | - | - |
Ingrid Delaet
LAW | General Counsel | - | 20-12-31 |
David Boyer
PRN | Corporate Officer/Principal | 44 | 19-09-29 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Christine Poon
BRD | Director/Board Member | 71 | 23-07-10 |
Chairman | 75 | 10-02-07 | |
Richard Pops
BRD | Director/Board Member | 62 | 98-03-31 |
Gary Lyons
BRD | Director/Board Member | 73 | 93-01-31 |
Leslie Norwalk
BRD | Director/Board Member | 58 | 98-03-31 |
Shalini Sharp
BRD | Director/Board Member | 49 | 20-02-02 |
Johanna Mercier
BRD | Director/Board Member | 54 | 21-04-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 99,507,490 | 97,058,874 ( 97.54 %) | 0 | 97.54 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
VOYAGER THERAPEUTICS, INC. 18.58% | 8,575,316 | 18.58% | 71,346,629 $ |
Company contact information
Neurocrine Biosciences, Inc.
12780 El Camino Real
92130, San Diego
+858 617 7600
http://www.neurocrine.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.83% | 13.84B | |
+1.10% | 105B | |
+9.29% | 104B | |
-3.00% | 22.09B | |
-11.89% | 21.98B | |
-26.59% | 20.17B | |
-5.20% | 19.49B | |
-6.58% | 17.75B | |
+7.46% | 11.64B | |
+28.56% | 11.55B |
- Stock
- Equities
- Stock Neurocrine Biosciences, Inc. - Nasdaq
- Company Neurocrine Biosciences, Inc.